Organogenesis Holdings Inc. reported first quarter ended March 31, 2026 results: revenue $36.3 million, net income Net loss of $53.2 million, EPS $(0.44) per share. Guidance lowered.
“Net revenue of $36.3 million for the first quarter of 2026”
Organogenesis Holdings Inc. — fact timeline
Source-grounded facts extracted from Organogenesis Holdings Inc.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Organogenesis Holdings Inc. amended First Amendment to Lease with 65 Dan Road SPE, LLC valued at Annual rent in 2027: $1,608,699.84 for 65 Dan Road and $3,161,377.89 for 150 Dan Road; lease term ex (effective 2025-12-22).
“On December 22, 2025, Organogenesis Inc. (“Organogenesis”), a wholly owned subsidiary of Organogenesis Holdings Inc. (the “Company”), entered into a First Amendment to Lease with 65 Dan Road SPE, LLC, as landlord, relating to the premises located at 65 Dan Road, Canton, Massachusetts (the “65 Dan Road Amendment”), and a separate First Amendment to Lease with Dan Road Associates, LLC, as landlord, relating to the premises located at 150 Dan Road, Canton, Massachusetts (the “150 Dan Road Amendment”, together with the 65 Dan Road Amendment, the “Lease Amendments”).”
Garrett Lustig was appointed as Director at Organogenesis Holdings Inc..
“On November 12, 2024, the Board appointed Garrett Lustig to the Board, effective immediately.”
Organogenesis Holdings Inc. reported first quarter ended March 31, 2024 results: revenue $110.0 million, net income $2.1 million, EPS $(0.02) per share. Guidance reaffirmed.
“Surgical & Sports Medicine markets, today reported financial results for the first quarter ended March 31st, 2024. First Quarter 2024 Financial Results Summary: • Net revenue of $110.0 million for the first quarter of 2024, an increase of $2.3 million compared to net revenue of $107.6 million for the first quarter of 2023. Net revenue for the first quarter of 2024”
Organogenesis Holdings Inc. reported the fiscal year ended December 31, 2023 results: revenue $433.1 million, net income Net income of $4.9 million. Guidance initiated.
“Net revenue of $433.1 million for the year ended December 31, 2023”
Organogenesis Holdings Inc. reported the fourth quarter ended December 31, 2023 results: revenue $99.7 million, net income Net loss of $0.6 million.
“Net revenue of $99.7 million for the fourth quarter of 2023”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.